Discover. Oncology最新文献

{"title":"A 23-gene multi-omics signature predicts prognosis and treatment response in non-small cell lung cancer.","authors":"Yinxu Zhang, Siwang Wang, Xiaoyang Chen, Guangyu Zhang, Yuxi Wang, Xiaomei Liu","doi":"10.1007/s12672-025-03243-2","DOIUrl":"10.1007/s12672-025-03243-2","url":null,"abstract":"","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1391"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of cell adhesion related signature for molecular subtyping and prognostic prediction in acute myeloid leukemia.","authors":"Caifang Zhao, Xiang Weng, Wei He","doi":"10.1007/s12672-025-03208-5","DOIUrl":"10.1007/s12672-025-03208-5","url":null,"abstract":"<p><strong>Background: </strong>Acute Myeloid Leukemia (AML) is a heterogeneous hematologic malignancy, characterized by complex molecular features that significantly impact prognosis and therapeutic responses. Despite considerable progress, effective risk stratification and predictive biomarkers for personalized therapies remain inadequate. The involvement of cell adhesion-related genes in the progression of AML has yet to be fully explored.</p><p><strong>Methods: </strong>AML patients were grouped into distinct molecular subtypes based on the expression patterns of cell adhesion-related genes. Enrichment analyses were subsequently performed to identify associated biological pathways. Differentially expressed genes were identified, and through Lasso regression and multivariate Cox regression, eight prognostically significant genes were selected. These genes were then used to construct a prognostic model, which was validated using external datasets. Furthermore, analyses of immune cell infiltration and drug sensitivity were conducted to evaluate the practical applicability of the model.</p><p><strong>Results: </strong>Two AML molecular subtypes were identified, each linked to distinct biological pathways. A prognostic model comprising 8 genes was developed, showing strong predictive power for overall survival and significant correlations with immune cell infiltration patterns. Drug sensitivity analyses identified potential therapeutic targets and candidate drugs, offering new directions for AML treatment.</p><p><strong>Conclusion: </strong>This study reveals novel AML subtypes driven by cell adhesion-related genes, providing insights into genetic heterogeneity, immune landscape, and therapeutic vulnerabilities. The developed prognostic model and identified therapeutic candidates offer valuable tools for prognosis prediction and personalized treatment strategies in AML.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1397"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of ultrasound in liver cancer from 2014 to 2024: bibliometric analysis and global trends.","authors":"Yaping Zhu, Yanyan Lu, Xinju Chen","doi":"10.1007/s12672-025-03177-9","DOIUrl":"10.1007/s12672-025-03177-9","url":null,"abstract":"<p><strong>Background: </strong>Liver cancer remains one of the most prevalent and lethal malignancies worldwide, highlighting the need for effective diagnostic and monitoring strategies. Ultrasound plays a vital role in the early diagnosis, monitoring, and treatment of liver cancer. However, no bibliometric analysis has been conducted in this field before. This study aims to provide a comprehensive overview of the knowledge structure and research hotspots related to the application of ultrasound in liver cancer via bibliometric methodologies.</p><p><strong>Methods: </strong>A search was performed in the Web of Science Core Collection database for English literature studies on the application of ultrasound in liver cancer from 2014 to 2024. Bibliometric analysis tools including VOSviewer, CiteSpace, and R Studio, were utilized to analyze global trends and research hotspots in this field.</p><p><strong>Results: </strong>A total of 2501 eligible publications, including 2048 articles and 453 reviews, were analyzed. In the past decade, both the annual output of publications and the citation rates have rapidly increased. The majority of published articles on this topic were originated in China (n = 832, 33.27%), followed by the United States (n = 586, 23.43%), and Italy (n = 222, 8.88%). Researchers from the United States have demonstrated high productivity, prominence, and influence in this area of research. Additionally, Sun Yat-sen University published the most papers (n = 64), whereas the University of Michigan had the highest average citation value (value = 60.28) related to research on the application of ultrasound in liver cancer. Notably, Singal, Amit G from the USA was the author with both the highest number of published articles and the highest average citation value.</p><p><strong>Conclusion: </strong>In recent years, rapid advancements in ultrasound research for liver cancer have been reported. Increasing evidence has illustrated the crucial role of ultrasound in the early diagnosis and monitoring of liver cancer.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1395"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucinous carcinoma of the breast: epidemiological, clinical, and prognostic characteristics; a single-center experience.","authors":"Omar Hamdy, Mosab Shetiwy, Mahmoud M Saber, Basma A Eldawody, Shorouq A Kassab, Mariam H Nabih, Mostafa Abdelhakiem, Mona Zaki, Shaimaa M Yussif, Saleh Saleh, Khaled Abdelwahab","doi":"10.1007/s12672-025-03146-2","DOIUrl":"10.1007/s12672-025-03146-2","url":null,"abstract":"<p><strong>Introduction: </strong>Mucinous (colloid) carcinoma (MC) of the breast typically affects postmenopausal and elderly women, with a more favorable prognosis compared to invasive breast carcinoma of no special type (IBC-NST). It is characterized by the presence of extracellular mucin and better outcomes. In our work, we presented a fifteen-year yield of a tertiary cancer center for MC.</p><p><strong>Methods: </strong>In this retrospective study, the data of the patients with MC from January 2009 to August 2023 were retrieved by searching the prospectively registered electronic database of the Oncology Center, Mansoura University. The patients' epidemiological, clinical, pathological, therapeutic, and oncological data were analyzed.</p><p><strong>Results: </strong>A total of 152 patients with the pathology of MC of the breast were included. The mean age of patients was 55.38 ± 13.82 years. Imaging revealed a unifocal lesion in 93 patients (61.2%). The mean mass size by imaging was 37.25 ± 20.21 mm. Positive lymph nodes (LNs) were detected by imaging in 71 (46.7%) patients. Pathological variants were either pure MC (42.1%) or mixed mucinous ductal carcinoma (57.9%). Luminal A was the most common subtype. Neoadjuvant therapy (NAT) was received by 34.8% of the patients. Mastectomy was done for 103 patients (68.2%). Axillary lymph node dissection was done for 122 patients (80.3%), and sentinel lymph node biopsy (SLNB) was done for 30 patients (19.7%). Adjuvant chemotherapy and radiotherapy were received by 65.1% and 60.8% of patients, respectively, while adjuvant hormonal therapy was received by 84.5%. The mean disease-free survival (DFS) was 43 ± 34.02 months, while the mean overall survival (OAS) was 44.5 ± 33.46 months. Seventeen patients (11.2%) were reported dead during the follow-up period.</p><p><strong>Conclusion: </strong>MC of the breast is a unique type of breast cancer. It may mimic benign lesions on imaging. The primary treatment for MC is mostly surgery, followed by adjuvant radiotherapy and systemic therapy. Comparing MC to IBC-NST, the former had a better prognosis and fewer lymphatic metastases, especially with pure MC, which shows a better prognosis.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1396"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sirtuin family in lung adenocarcinoma.","authors":"Cui Chen, Xiumin Liu, Zhe Xu, Juan Xu, Lei Gong, Xiaobo Wang","doi":"10.1007/s12672-025-03217-4","DOIUrl":"10.1007/s12672-025-03217-4","url":null,"abstract":"<p><p>Lung cancer is a highly aggressive malignancy that accounts for one of the greatest mortality rate in humans globally. Among various types of lung malignancies, lung adenocarcinoma (LUAD) stands out as the most common form. Sirtuins (SIRTs) are class III nicotinamide adenine dinucleotide (NAD⁺)-dependent histone deacetylases that comprise seven members (SIRT1-7). Sirtuins play a essentail role in various biological processes such as cellular differentiation, inflammation, apoptosis, metabolism, immune response, oxidative stress, mitochondrial homeostasis, and autophagy. Therefore, it is considered a potential therapeutic target for different kinds of pathologies including cancer, kidney diseases, and other conditions. While several reviews have been published on sirtuins and lung cancer, there remains a gap in the review regarding sirtuins specifically in LUAD. Herein, we not only elaborate on the roles of different sirtuins and their mechanisms in LUAD, but also discuss the potential application of sirtuins inhibitors and activators for LUAD therapy.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1398"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12286909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in radiotherapy for mouth neoplasms: emerging technologies and future perspectives.","authors":"Xuhong Liu, Zhuoya Zhang, Xinyu Deng, Zekun Lang, Jianrong Wang","doi":"10.1007/s12672-025-03249-w","DOIUrl":"10.1007/s12672-025-03249-w","url":null,"abstract":"<p><p>Oral cancer is a common malignant tumor of the head and neck region, significantly impacting human health and quality of life. Radiotherapy has become an essential component of treatment, often used in combination with surgery and/or chemotherapy. Advances in radiotherapy techniques, such as intensity-modulated radiotherapy, image-guided radiotherapy, and proton beam therapy, have markedly improved clinical outcomes. Intensity-modulated radiotherapy, for example, has demonstrated 5-year overall survival rates ranging from 60 to 75%, with better local control and reduced toxicity compared to conventional radiotherapy. Proton therapy has shown promising results in sparing normal tissues and achieving high-dose conformity, leading to improved quality of life and comparable tumor control. This review highlights the recent technological developments, explores underlying molecular mechanisms and predictive biomarkers, and discusses future directions in the radiotherapeutic management of oral cancer, aiming to provide clinically valuable insights and evidence-based recommendations.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1392"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase separation-related gene signature for prognosis prediction and immunotherapy response evaluation in gastric cancer with targeted natural compound discovery.","authors":"Yanjuan Jia, Yuanyuan Ma, Zhenhao Li, Wenze Zhang, Rukun Lu, Wanxia Wang, Chaojun Wei, Chunyan Wei, Yonghong Li, Xiaoling Gao, Tao Qu","doi":"10.1007/s12672-025-03129-3","DOIUrl":"10.1007/s12672-025-03129-3","url":null,"abstract":"<p><strong>Background: </strong>Aberrant phase separation (PS) has emerged as a pivotal pathogenic mechanism in cancer development. However, its prognostic significance and influence on the tumor immune microenvironment in gastric cancer (GC) remain largely unexplored. This study aimed to develop a PS-related risk model for predicting clinical outcomes and immunotherapy response, and to identify potential natural small-molecule compounds targeting proteins within this PS-related network.</p><p><strong>Methods: </strong>We integrated transcriptomic data from the TCGA-STAD and GSE62254 datasets with four PS-related databases (including DrLLPS, PhaSepDB, PhaSePro, and LLPSDB) to identify candidate signature genes. The prognostic model was developed using least absolute shrinkage and selection operator (LASSO) regression and validated in both cohorts. Immune checkpoint inhibitor (ICI) response between PS-related high- and low-risk groups was evaluated using TIDE algorithm scores. Potential therapeutic agents targeting signature genes were screened via Connectivity Map and HERB database analyses, followed by molecular docking validation.</p><p><strong>Results: </strong>By Integrating analysis of the differential expression dataset from TCGA-STAD (n = 407, 375 tumor/32 normal) with prognosis-related dataset and PS-related dataset, we identified 78 candidate genes and developed a robust 21-gene risk prediction model. The model effectively stratified GC patients into high-risk and low-risk subgroups, with consistent performance in the independent GSE62254 validation cohort (n = 300, tumor). Compared to low-risk patients, high-risk patients exhibited poorer survival, a more immunosuppressive microenvironment, and a reduced response to immunotherapy. Moreover, computational screening identified 18 potential therapeutic natural compounds, 13 of which showed high-affinity binding to signature genes (docking scores > 6.0).</p><p><strong>Conclusions: </strong>Our study developed a novel PS-related risk model that predicts GC outcomes, characterizes tumor immune microenvironment, evaluates immunotherapy response, and identifies targeting small molecules. These findings advance the understanding of PS regulation in GC and provide a framework for personalized therapy.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1393"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNF213 governs divergent tumor-immune dynamics across human cancers: a prognostic biomarker for immunotherapy stratification.","authors":"Jinpeng Wen, Zhekuan Lv, Mojiao Lu, Chuanming Zheng, Changtian Yin","doi":"10.1007/s12672-025-03237-0","DOIUrl":"10.1007/s12672-025-03237-0","url":null,"abstract":"<p><strong>Purpose: </strong>RNF213 encodes one of the largest E3 ubiquitin ligases in the human proteome, playing essential roles in ubiquitination, DNA damage repair, and immune system regulation. Although RNF213 has been extensively studied in Moyamoya disease, its involvement in cancer biology remains insufficiently understood. This study seeks to conduct a comprehensive pan-cancer analysis to explore RNF213 expression, mutation characteristics, its correlation with clinical outcomes, and its potential as a prognostic biomarker and a therapeutic target, particularly in the context of immunotherapy.</p><p><strong>Methods: </strong>Leveraging data from The Cancer Genome Atlas (TCGA) and additional publicly available datasets, we performed a systematic analysis of RNF213 expression patterns, mutation frequencies, and their relationships with clinical outcomes. We also conducted survival analyses to assess the impact of RNF213 expression on the efficacy of immune checkpoint blockade therapies.</p><p><strong>Results: </strong>RNF213 demonstrated variable expression levels across different cancer types, with notable overexpression observed in glioblastoma and endometrial carcinoma, while underexpression was detected in lung adenocarcinoma and prostate adenocarcinoma. Elevated RNF213 expression was linked to unfavorable survival outcomes in acute myeloid leukemia and low-grade glioma, whereas it was associated with better survival in sarcoma and skin cutaneous melanoma. RNF213 expression showed a positive association with immune-related genes and immune cell infiltration, particularly in glioblastoma and breast cancer. Furthermore, patients with high RNF213 expression experienced significant survival advantages when receiving combined anti-PD-1 and anti-CTLA-4 immunotherapies.</p><p><strong>Conclusion: </strong>This study highlights RNF213's dual functionality in tumor progression and immune modulation, underscoring its potential as both a prognostic biomarker and a therapeutic target. The findings suggest that RNF213 may play a pivotal role in determining immunotherapy outcomes, warranting further exploration into its underlying mechanisms and clinical applications.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1394"},"PeriodicalIF":2.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12287489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of mitochondrial signature (MS) for the prognosis of ovarian cancer.","authors":"Miao Ao, You Wu, Kunyu Wang, Haixia Luo, Wei Mao, Anqi Zhao, Xiaomeng Su, Yan Song, Bin Li","doi":"10.1007/s12672-025-02892-7","DOIUrl":"https://doi.org/10.1007/s12672-025-02892-7","url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OV) continues to be the most lethal type of gynecological cancer with a poor prognosis. During tumorigenesis and cancer advancement, mitochondria are key players in energy metabolism. This study focuses on exploring the mitochondria-related genes for the prognosis of OV.</p><p><strong>Methods: </strong>RNA expression profiles and single-cell data were acquired from The Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC), and Gene Expression Omnibus databases for screening and validating mitochondria-related differentially expressed genes (DEGs). After univariate Cox analysis, prognostic genes were carried out for modeling mitochondria signature (MS) based on 101 combinations of 10 machine learning algorithms. Functional enrichment analysis was performed on this prognostic gene set. Immune infiltration analysis was performed between MS groups. Validation for the prognostic model gene OAT was performed to identify the prognostic significance, combined with in vitro experiments to explore its expressions in OV cells. qRT-PCR assay was performed to examine the expression of OAT in human ovarian cancer cell samples and normal ovarian epithelial cells.</p><p><strong>Results: </strong>A total of 21 prognostic mitochondria-related DEGs were identified for reliably constructing the model MS with excellent prognostic performance in OV. GO and KEGG analysis confirmed these genes were enriched in the generation of precursor metabolites and energy. It illustrated more lymphocyte infiltration in the high MS group than low MS group. OAT served as a novel biomarker for OV patients, showing poor survival in OV patients with high expression of OAT. qPCR assays confirmed its significantly high expression in human ovary cancer cell lines.</p><p><strong>Conclusions: </strong>The MS offers tailored risk evaluations and immunotherapy treatments for each OV patient. MS model gene OAT has been recognized as a new oncogene for OV linked to immune escape.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1388"},"PeriodicalIF":2.8,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expression of interleukin 1-alpha, interleukin 6 and CD 10 in predicting recurrence of ameloblastoma.","authors":"Nurhazwani Mohd Danil, Bogahawatte Samarakoon Mudiyanselage Samadarani Siriwardena, Yet Ching Goh, Wanninayake Mudiyanselage Tilakaratne","doi":"10.1007/s12672-025-03235-2","DOIUrl":"https://doi.org/10.1007/s12672-025-03235-2","url":null,"abstract":"<p><strong>Purpose: </strong>Ameloblastoma (AM) is a clinically significant odontogenic tumour known for its local invasive and high post-treatment recurrence risk. Despite advancements in surgical techniques, predicting recurrence remains challenging. The role of immunomarkers in predicting recurrence of ameloblastoma remains non-conclusive. The aim of this study is to investigate the predictability of recurrence using selected immune markers.</p><p><strong>Methods: </strong>42 AM samples comprising 16 non-recurrent AM (AMNR), 13 primary tumour of recurrent AM (PAMR), and 13 recurrent AM from the same patient as PAMR (RAM) were immunohistochemically examined for the expression of interleukin 1-alpha (IL-1α), interleukin 6 (IL-6) and CD 10. Immunoreactive scoring (IRS) was used to assess the expression levels. The expression levels were further analyzed for the correlation with demographic and clinicopathological parameters of interest.</p><p><strong>Results: </strong>The three markers were heterogeneously expressed in the ameloblastoma samples (IL-1α = 97.6%; IL-6 = 97.6% and CD 10 = 90.5%). Major findings were the upregulation of IL-6 (RAM > PAMR > AMNR) in RAM, while IL-1α and CD 10 scored higher in AMNR (AMNR > PAMR > RAM). Further correlation with clinicopathological parameters showed significant association between IL-1α expression with histopathological variants in AMNR (p = 0.03) and PAMR (p = 0.002). IL-6 expression was significantly correlated with tumour locality in AMNR (p = 0.01), and CD 10 showed significant correlation with tumour locality in PAMR (p = 0.02) and subsites of tumour locality in PAMR (p = 0.005) and RAM (p = 0.002).</p><p><strong>Conclusion: </strong>The upregulation of IL-6 in recurrent ameloblastoma may predict its potential for recurrence. However, this interpretation should be considered tentative due to the inherent limitations of the study. Immunoexpression of IL-1α and CD 10 requires further investigation to elucidate their roles in tumourigenesis and invasiveness of ameloblastoma.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1390"},"PeriodicalIF":2.8,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144689481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}